It all started with the mission to improve the life of at least one patient.
We’ve now lost count.
But our mission remains just as personal.
Behind every scan is a story
Many of us at icometrix have seen someone we love lose words, memories, or independence to a brain disorder.
That’s why our mission is personal.
A life interrupted, a family searching for answers, a care team trying to make the right call.
We build technology to bring clarity in those moments. To help clinicians see what matters, and to help patients hold on to who they are.
From university spin-off to global leaders
2011
icometrix was founded as a spin-off from two Belgian universities and hospitals
2014
Initial development of icobrain completed, supported by multiple pharma partnerships – laying the foundation for FDA clearance
2015 - 2016
Achieved CE marking for icobrain, followed by first FDA clearance – enabling commercialization across Europe and launching our US presence
2017
Expanded icobrain to multiple neurological conditions, including Alzheimer's, stroke, and traumatic brain injury
2020
Launched icolung during the COVID-19 pandemic - delivered free AI lung analyses to over 45,000 individuals.
2020
Launched icompanion, a patient-oriented care platform empowering people with MS to track their health and stay connected with their care team
2021
Secured multiple patents for AI-driven medical imaging technologies
2023
icobrain is the first AI-based neuroradiology solution to receive a CPT-III® code assignment from the AMA, based on extensive clinical validation.
2024
icobrain aria became the only FDA-cleared CADe/CADx solution in neuroradiology - meeting the urgent need for ARIA monitoring in Alzheimer’s care
%20(11).png)
.jpg)
%20(9).png)
Meet the people who make all of this happen
.jpeg)
.jpeg)
